References
Chan AY, Choi EH, Yuki I, et al. Cerebral vasospasm after subarachnoid hemorrhage: developing treatments. Brain Hemorrhages. 2021;2:15–23.
Endo H, Hagihara Y, Kimura N, et al. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022;137:1707–1717.
Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10:618–625.
Macdonald RL, Higashida RT, Keller E, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43:1463–1469.
Bruder N, Higashida R, Santin-Janin H, et al. The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. BMC Neurol. 2022;22:492. https://doi.org/10.1186/s12883-022-03002-8.
Maeda H, Izumo T, Okamura K, et al. Evolving approaches in the management of patients with subarachnoid hemorrhage from 2002 to 2022: the impact of clazosentan and treatment modalities on outcomes. Brain Hemorrhages. 2024;2:55–61. https://doi.org/10.1016/j.hest.2023.11.006.
Akamatsu Y, Chida K, Miyoshi K, et al. Fluid balance management with loop diuretics in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a case series. Brain Hemorrhages. 2024;2:74–78. https://doi.org/10.1016/j.hest.2023.10.003.
Shikata E,, Yamaguchi I, Korai M. Could clazosentan, first approved in Japan, improve neurological prognosis after subarachnoid hemorrhage in combination with modified water-electrolyte management? Brain Hemorrhages. 2024;2:91–97. https://doi.org/10.1016/j.hest.2023.10.005.
Nishii R, Ohta T, Fukui N,, et al. A high cardiothoracic ratio increases the risk of severe pulmonary complications after early initiation of clazosentan in patients with aneurysmal subarachnoid hemorrhage. Brain Hemorrhages. 2024;2:85–90. https://doi.org/10.1016/j.hest.2023.11.007.
Suzuki H, Nakajima H, Ichikawa T, et al. Beneficial effects of clazosentan add-on treatment on delayed cerebral microcirculatory disturbances after aneurysmal subarachnoid hemorrhage. Brain Hemorrhages. 2024;2:62–68. https://doi.org/10.1016/j.hest.2023.10.006.
Itazu T, Ikedo T, Tsutsui T, et al. Impact of strict fluid management on the treatment outcome of clazosentan for cerebral vasospasm. Brain Hemorrhages. 2024;2:69–73. https://doi.org/10.1016/j.hest.2023.12.001.
